MGC Pharmaceuticals is expected to benefit from the United Nations’ (UN) decision to remove cannabis and its derivatives from schedule IV following recommendations from the World Health Organisation (WHO). Cannabis and its derivatives will now be contained under Schedule I of the 1961 UN Single Convention on Narcotic Drugs. The removal of cannabis and its derivatives from schedule IV means that the UN accepts the opinion of the WHO that cannabis is not “liable to produce ill-effects” on the scale of other drugs in Schedule IV, and that cannabis has significant potential therapeutic value. This removal, alongside other legislative changes, announced this year, further demonstrates the rapidly changing political perspectives on cannabis and the use of cannabis for medicinal purposes.
Mmp News Author, Medical Marijuana Program Connection, 12/03/2020 06:12:27
Open article: https://mmpconnect.com/mgc-pharmaceuticals-well-positioned-to-benefit-from-uns-decision-to-reclassify-cannabis-as-less-dangerous-drug/